TheStreet

Blue Apron Holdings Inc (NYSE: APRN) IPO in late June couldn't have come at a worse time. The company sells to consumers a food delivery kit, but it's far from alone in the space and faces competition from several other startups. An even bigger threat is the possibility of Amazon.com, Inc...

In a world that’s been described as dog-eat-dog, where “survival of the fittest” and like cliches abound, business competition is fierce. With limited resources and limited customers, some companies, like the people running them, have found strategic treaties and partnerships...

A deal announced over 1.5 years ago still hangs in the balance. Whether the deal clears the regulatory hurdle has become a heated debate in itself. With the passing of each day, pessimism is abounding, with the scuttling of a few mega healthcare deals throwing in the possibility of the...

Sears Holdings Corp (NASDAQ: SHLD) is fighting hard to remain relevant in the retail environment, but at least one former executive isn't offering any moral support or encouragement. In an interview with TheStreet, Sears Canada's former CEO Mark Cohen blasted the company, including its most senior...

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are up more than 6.5 percent Friday after the company reported first-quarter net revenue from EXONDYS 51 of $16.3 million and guided for $95 million in revenue for the full year, up from previous guidance of $80 million. In addition to the revenue beat...

Shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) were trading lower by around 10 percent Thursday morning, even though the company reported positive, top-line data from an ongoing clinical trial. Corbus has been exploring its Anabasum (Resunab) therapy in a Phase 2 study for the...

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are down more than 20 percent Tuesday after nearly tripling in a month’s time. For traders wondering how the stock lost its mojo, the Twitter feed of TheStreet columnist Adam Feuerstein tells the story. Related Link: 7 Tweets That Ruined...

Trevena Inc (NASDAQ: TRVN), a clinical-stage biopharmaceutical company that focuses on therapeutics that use an approach to target G protein coupled receptors (GPCRs), saw its shares plummet around 30 percent Tuesday morning despite a positive development in Phase 3 trials. Trevena announced...

The tricky thing about pharmaceuticals is that, in theory, they’re meant to write themselves out of the equation. True success — a world without disease — would also mean a world without drugs and a world without pharmaceuticals. When drug companies are successful, they cease to...

We’re looking at a whole new culture. For the first time in Super Bowl history, PepsiCo, Inc. (NYSE: PEP) will forgo ads for its hallmark can of Pepsi and instead push its sugar-free beverage line. “It’s got to start with consumer demand,” chief marketing officer Seth...